Market Overview

Wall Street's M&A Chatter From April 28-30: Walgreens-Rite Aid, Anthem-Cigna, Fox-Tribune Media, Sarepta

Share:

The following are the M&A deals, rumors and chatter circulating on Wall Street for Friday, April 28, through Sunday, April 30, 2017.

Walgreens Set to Certify FTC Compliance within Days for Rite Aid Deal

The Rumor:

Walgreens Boots Alliance Inc (NASDAQ: WBA) is said to likely to certify compliance within days for its merger with Rite Aid Corporation (NYSE: RAD), according to sources as reported by the New York Post on Friday. A month ago, Walgreens had given the FTC 30 days’ notice it was going to certify it had supplied all the information necessary to rule on the deal.

The decision by the FTC is expected within 90 days following the certification.

Rite Aid closed Friday at $4.00, up $0.05.

Appeals Court Affirms Decision to Block Anthem/Cigna Deal

The Court Decision:

The U.S. Court of Appeals for the District of Columbia Circuit on Friday affirmed a decision by U.S. District Judge Amy Berman Jackson to block the Anthem Inc. (NYSE: ANTM) acquisition of Cigna Corp. (NYSE: CI) on antitrust issues, as reported by the Wall Street Journal. The three-judge panel upheld Judge Jackson's February ruling that the merger would limit competition among large health insurers, rejecting Anthem's argument that the trial court had failed to consider the billions of dollars in cost savings to be generated from the merger.

Anthem said it was reviewing the opinion and will carefully evaluate its options. Cigna said it was continuing to work through the litigation process in the Delaware Court of Chancery.

Cigna closed at $156.37, up $0.16. Anthem closed at $177.89, down $0.41.

Feuerstein Speculates about Possible Sanofi Takeover of Sarepta

The Rumor:

Shares of Sarepta Therapeutics (NASDAQ: SRPT) rose Friday following a from TheStreet's Adam Feuerstein speculating on a potential acquisition by drug-maker Sanofi (NYSE: SNY). Feuerstein cited the departure of Sarepta CEO Ed Kaye, as well as Sanofi executive Dr. Jean-Paul Kresse, saying he will not to stand for re-election to Sarepta's boards due to a potential conflict of interest.associated with his future endeavors."

Sanofi does have a drug for DMD in its pipeline and Exondys 51 would be a good fit for Sanofi, the article mentioned. Sanofi's Genzyme unit is moving to new headquarters in Cambridge, MA., right around the corner from Sarepta.

Sarepta closed at $36.26, up $1.54.

21st Century Fox, Blackstone Discussing Joint Bid for Tribune Media

The Rumor:

Twenty-First Century Fox Inc (NASDAQ: FOXA) is in talks with Blackstone Group LP (NYSE: BX) to jointly bid to acquire Tribune Media Co (NYSE: TRCO), according to sources as reported by the Financial Times on Sunday. The offer would be made via a joint venture, the sources said.

Earlier this month, Bloomberg reported Sinclair Broadcast Group Inc. was ready to bid in the high $30's per share for Tribune Media and was aiming to finalize a deal prior to their earnings release in May.

Tribune Media closed at $36.56, down $0.28.

Posted-In: M&A News Rumors

 

Related Articles (BX + ANTM)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

A Peek Into The Markets: U.S. Stock Futures Gain Ahead Of Economic Reports

Neurotrope's Phase 2 Drug To Treat Alzheimer's Doesn't Clear Threshold For Statistical Significance